Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.16 Million USD | 55.76% |
| 2022 | -7.16 Million USD | 61.77% |
| 2021 | -18.72 Million USD | -167.18% |
| 2020 | -7.01 Million USD | 22.72% |
| 2019 | -9.07 Million USD | 44.56% |
| 2018 | -16.36 Million USD | -5.32% |
| 2017 | -15.53 Million USD | -20.88% |
| 2016 | -12.85 Million USD | 2.23% |
| 2015 | -13.14 Million USD | -59.39% |
| 2014 | -8.24 Million USD | -155.76% |
| 2013 | -3.22 Million USD | 34.12% |
| 2012 | -4.89 Million USD | 17.58% |
| 2011 | -5.93 Million USD | -72.96% |
| 2010 | -3.43 Million USD | -131.15% |
| 2009 | -1.48 Million USD | -191.13% |
| 2008 | -510.19 Thousand USD | -981.81% |
| 2007 | -47.16 Thousand USD | -38.21% |
| 2006 | -34.12 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -179 Thousand USD | -29.22% |
| 2023 Q2 | -375 Thousand USD | 73.74% |
| 2023 Q1 | -1.42 Million USD | 21.8% |
| 2023 Q3 | -729 Thousand USD | -94.4% |
| 2023 Q4 | -681 Thousand USD | 6.58% |
| 2023 FY | -3.16 Million USD | 55.76% |
| 2022 Q1 | -2.05 Million USD | 19.84% |
| 2022 FY | -7.16 Million USD | 61.77% |
| 2022 Q4 | -1.82 Million USD | -20.61% |
| 2022 Q3 | -1.51 Million USD | 19.17% |
| 2022 Q2 | -1.87 Million USD | 8.9% |
| 2021 Q2 | -6.17 Million USD | -426.34% |
| 2021 Q3 | -3.96 Million USD | 35.86% |
| 2021 Q4 | -2.56 Million USD | 35.23% |
| 2021 FY | -18.72 Million USD | -167.18% |
| 2021 Q1 | -1.17 Million USD | 20.64% |
| 2020 FY | -7.01 Million USD | 22.72% |
| 2020 Q2 | -2.62 Million USD | -69.35% |
| 2020 Q1 | -1.55 Million USD | -2.31% |
| 2020 Q3 | -995 Thousand USD | 62.1% |
| 2020 Q4 | -1.47 Million USD | -48.54% |
| 2019 Q1 | -2.05 Million USD | 57.83% |
| 2019 Q3 | -1.13 Million USD | 71.42% |
| 2019 Q4 | -1.51 Million USD | -33.25% |
| 2019 FY | -9.07 Million USD | 44.56% |
| 2019 Q2 | -3.97 Million USD | -94.1% |
| 2018 Q2 | -4.51 Million USD | 0.35% |
| 2018 Q4 | -4.86 Million USD | -98.49% |
| 2018 FY | -16.36 Million USD | -5.32% |
| 2018 Q1 | -4.53 Million USD | 13.59% |
| 2018 Q3 | -2.44 Million USD | 45.79% |
| 2017 Q3 | -3.9 Million USD | -16.23% |
| 2017 FY | -15.53 Million USD | -20.88% |
| 2017 Q4 | -5.24 Million USD | -34.44% |
| 2017 Q2 | -3.35 Million USD | -10.9% |
| 2017 Q1 | -3.02 Million USD | 6.66% |
| 2016 Q2 | -3.32 Million USD | -28.95% |
| 2016 Q3 | -3.7 Million USD | -11.62% |
| 2016 Q1 | -2.57 Million USD | 16.9% |
| 2016 FY | -12.85 Million USD | 2.23% |
| 2016 Q4 | -3.24 Million USD | 12.54% |
| 2015 Q1 | -4.39 Million USD | -31.58% |
| 2015 Q3 | -2.89 Million USD | -5.12% |
| 2015 Q2 | -2.75 Million USD | 37.34% |
| 2015 FY | -13.14 Million USD | -59.39% |
| 2015 Q4 | -3.1 Million USD | -7.12% |
| 2014 Q4 | -3.34 Million USD | -43.14% |
| 2014 FY | -8.24 Million USD | -155.76% |
| 2014 Q3 | -2.33 Million USD | -46.16% |
| 2014 Q2 | -1.59 Million USD | -63.4% |
| 2014 Q1 | -977.02 Thousand USD | 14.3% |
| 2013 FY | -3.22 Million USD | 34.12% |
| 2013 Q1 | -468.99 Thousand USD | 70.01% |
| 2013 Q2 | -748.82 Thousand USD | -59.67% |
| 2013 Q3 | -866.55 Thousand USD | -15.72% |
| 2013 Q4 | -1.14 Million USD | -31.57% |
| 2012 Q4 | -1.56 Million USD | -406.75% |
| 2012 FY | -4.89 Million USD | 17.58% |
| 2012 Q2 | -2.06 Million USD | -114.3% |
| 2012 Q1 | -961.45 Thousand USD | 24.3% |
| 2012 Q3 | -308.61 Thousand USD | 85.02% |
| 2011 FY | -5.93 Million USD | -72.96% |
| 2011 Q3 | -2.29 Million USD | -71.75% |
| 2011 Q4 | -1.27 Million USD | 44.72% |
| 2011 Q1 | -1.03 Million USD | -14.58% |
| 2011 Q2 | -1.33 Million USD | -29.48% |
| 2010 FY | -3.43 Million USD | -131.15% |
| 2010 Q2 | -1.19 Million USD | -121.64% |
| 2010 Q4 | -901.64 Thousand USD | -12.72% |
| 2010 Q3 | -799.86 Thousand USD | 32.98% |
| 2010 Q1 | -538.45 Thousand USD | -69.45% |
| 2009 FY | -1.48 Million USD | -191.13% |
| 2009 Q4 | -317.77 Thousand USD | 51.16% |
| 2009 Q3 | -650.57 Thousand USD | -100.62% |
| 2009 Q2 | -324.28 Thousand USD | -68.28% |
| 2009 Q1 | -192.7 Thousand USD | 10.93% |
| 2008 Q1 | -15.57 Thousand USD | 3.92% |
| 2008 Q2 | -117.63 Thousand USD | -655.49% |
| 2008 FY | -510.19 Thousand USD | -981.81% |
| 2008 Q3 | -176.2 Thousand USD | -49.8% |
| 2008 Q4 | -216.35 Thousand USD | -22.78% |
| 2007 Q2 | -13.42 Thousand USD | -42.22% |
| 2007 Q3 | -9100.00 USD | 32.19% |
| 2007 Q1 | -9436.00 USD | 0.0% |
| 2007 Q4 | -16.2 Thousand USD | -78.08% |
| 2007 FY | -47.16 Thousand USD | -38.21% |
| 2006 FY | -34.12 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -137.227% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 54.632% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.98% |
| Nascent Biotech, Inc. | -2.08 Million USD | -51.747% |
| Rebus Holdings, Inc. | -1.02 Million USD | -210.588% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.864% |
| Qrons Inc. | -789.34 Thousand USD | -301.344% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -400.943% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.939% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -662.493% |
| Skye Bioscience, Inc. | -37.64 Million USD | 91.584% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.774% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 51.826% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1058.733% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.013% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -9.529% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -74.015% |
| Mesoblast Limited | -87.95 Million USD | 96.398% |
| Marizyme, Inc. | -65.34 Million USD | 95.152% |
| Genus plc | 7.9 Million USD | 140.101% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 70.914% |
| Pharming Group N.V. | -10.54 Million USD | 69.966% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -46.003% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 14.615% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 64.179% |
| ContraFect Corporation | -65.15 Million USD | 95.138% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 35.163% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -83.391% |
| IMV Inc. | -36.48 Million USD | 91.317% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 60.693% |
| MultiCell Technologies, Inc. | -380.07 USD | -833430.665% |
| ONE Bio Corp. | 8.67 Million USD | 136.512% |
| Accustem Sciences Inc. | -3.74 Million USD | 15.439% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.871% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -150.013% |
| Q BioMed Inc. | -2.05 Million USD | -54.379% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 15.135% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -33.061% |
| Biomind Labs Inc. | -1.21 Million USD | -160.887% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.696% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -2.135% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 59.914% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -62.524% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -21053.846% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 80.04% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 45.541% |
| GB Sciences, Inc. | -1.36 Million USD | -132.654% |
| Alpha Cognition Inc. | -13.77 Million USD | 76.998% |
| HST Global, Inc. | -146.21 Thousand USD | -2066.746% |
| CSL Limited | 2.64 Billion USD | 100.12% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -80.536% |
| Halberd Corporation | -79.67 Thousand USD | -3876.103% |
| Enzolytics Inc. | -2.17 Million USD | -45.533% |
| Agentix Corp. | -1.37 Million USD | -130.532% |
| Resverlogix Corp. | -3.61 Million USD | 12.244% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 0.108% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.926% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3332.653% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 145.75% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 20.262% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -4.688% |
| AVAX Technologies, Inc. | -6.41 Million USD | 50.605% |
| Zenith Capital Corp. | -10.59 Million USD | 70.102% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.682% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -13530.497% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 23.588% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5141.509% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -57.996% |
| Kadimastem Ltd | -3.3 Million USD | 4.215% |
| Helix BioMedix, Inc. | -1.05 Million USD | -199.984% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 17.046% |
| BioStem Technologies, Inc. | -8.48 Million USD | 62.655% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -617.767% |
| LadRx Corporation | 400.44 Thousand USD | 891.124% |
| Cell Source, Inc. | -5.32 Million USD | 40.465% |
| Regen BioPharma, Inc. | 1.02 Million USD | 409.524% |
| Regen BioPharma, Inc. | 1.02 Million USD | 409.524% |
| NovAccess Global Inc. | -4.76 Million USD | 33.574% |
| Affymax, Inc. | -14.42 Million USD | 78.037% |
| Itoco Inc. | -1.86 Million USD | -69.503% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 28.689% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -89.814% |
| Mobile Lads Corp. | -2.26 Million USD | -39.973% |
| CytoDyn Inc. | -49.84 Million USD | 93.644% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3908.452% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1288.7% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -236.474% |
| SYBLEU INC | -180.3 Thousand USD | -1657.033% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -96.436% |
| International Stem Cell Corporation | -131 Thousand USD | -2318.321% |
| Bioxytran, Inc. | -4.28 Million USD | 25.981% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -5737.264% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -25.205% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.41% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -49.858% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -305.693% |
| Neutra Corp. | -233.46 Thousand USD | -1256.949% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 84.387% |
| PureTech Health plc | -65.69 Million USD | 95.178% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 85.103% |
| IXICO plc | -1.17 Million USD | -168.93% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 68.087% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.455% |
| CSL Limited | 2.64 Billion USD | 100.12% |
| Cellectis S.A. | -103.17 Million USD | 96.929% |